PYC THERAPEUTICS LIMITED (PYC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PYC - PYC THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.01
Index: ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.12

02 Jul
2024

0.000

OPEN

$0.13

0.000

HIGH

$0.13

2,273,390

LOW

$0.12

TARGET
$0.10 -16.7% downside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
PYC: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 0.7 - 0.7 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-0.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx0.8
Net Operating Cash Flow xxxxxxxxxxxxxxx-24.4 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-67.92 %
Return on Invested Capital xxxxxxxxxxxxxxx-67.10 %
Return on Assets xxxxxxxxxxxxxxx-55.23 %
Return on Equity xxxxxxxxxxxxxxx-67.92 %
Return on Total Capital xxxxxxxxxxxxxxx-112.05 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-24.9 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx16 M
Price To Book Value xxxxxxxxxxxxxxx6.89

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx1 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx38 M
Research & Development xxxxxxxxxxxxxxx35 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

21/05/2024

1

Initiation of coverage with Speculative Buy

$0.10

-16.67%

Bell Potter initiates coverage on clinical-stage biotech company PYC Therapeutics with a Speculative Buy rating.

The company is harnessing its differentiated RNA drug development platform to treat rare inherited diseases, and is currently progressing three drug candidates through clinical development.

The broker strongly believes PYC will succeed withe these drug candidates and expects multiple early and mid-stage clinical readouts will come to fruition over the next 18 months. 

A 10c target price is set.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.70 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Stockbroker Research History >

PYC STOCK CHART

FNArena News on PYC

1
Australian Broker Call *Extra* Edition – Jul 01, 2024

Jul 01 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – May 08, 2024

May 08 2024 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Mar 21, 2024

Mar 21 2024 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Mar 14, 2024

Mar 14 2024 - Daily Market Reports
5
Rudi’s View: February 2024 Is A Blue Sky Affair

Feb 14 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Radiopharm Theranostics

11:00 AM - Small Caps
2
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
3
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps
4
Is The Long Wait For CSL About To End?

May 30 2024 - Technicals
5
Dr Boreham’s Crucible: Invion

May 13 2024 - Small Caps
6
Dr Boreham’s Crucible: Race Oncology

Apr 09 2024 - Small Caps
7
The Power Of New Weight-Loss Drugs

Apr 03 2024 - International
8
Dr Boreham’s Crucible: Neuren Pharmaceuticals

Mar 11 2024 - Small Caps
9
Spotlight On ASX-Listed Cannabis Companies

Jan 31 2024 - Small Caps
10
Transformational Trial Results For Neuren Pharmaceuticals

Dec 20 2023 - Small Caps